leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma to conduct telemedicine coronavirus trials of AP-003 to ease access for patients

Despite the volume of coronavirus cases, including more than 8 million in the US, just 60,000 have been involved in any sort of therapeutic trial that is not vaccine related

Coronavirus graphic
BetterLife’s clinical trial will test AP-003, an inhaled recombinant human alpha 2b interferon drug, against a placebo

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) (FRA:NPAU) announced Wednesday that its coronavirus trials are being conducted virtually to make them more accessible and convenient for patients.  

The company noted that despite the volume of coronavirus cases, including more than 8 million in the US, just 60,000 have been involved in any sort of therapeutic trial that is not vaccine-related, as estimated by the medical intelligence publication Evaluate.  

BetterLife’s goal for trials of its drug AP-003 is to use technology to make life easier and simpler for patients. The company’s trials have been designed to promote study participation and streamline data collection by allowing patients with mild-to-moderate COVID-19 to self-identify for potential trial enrollment following COVID-19 testing. 

READ: BetterLife Pharma launches marketed private placement offering of special warrants for gross proceeds of up to $5 million

Trial consent will be obtained virtually and the trial will be conducted via telemedicine from the participant’s home, the company said. This allows the symptomatic participant to remain in their home but to have daily contact with medical personnel.

The use of telemedicine also decreases the risk of coronavirus exposure to study personnel. All data collection will be electronic, allowing for rapid review.

‘’Many shareholders have inquired as to our progress in this regard, and we are pleased to announce that we have made significant strides in advancing these trials in Australia,” CEO Ahmad Doroudian said in a statement. “Using new and innovative technology will allow us to be in the vanguard of clinical study design, to easily meet our enrolment goals, and to expedite any potential FDA approval and commercialization of AP-003 for the treatment of COVID-19.”

BetterLife’s clinical trial will test AP-003, an inhaled recombinant human alpha 2b interferon drug, against a placebo. The trial, which the company claims is the first of its kind in Australia, is expected to recruit 150 patients.

Interferons are a natural part of the body’s innate immune system that are induced by viral infection, the company said, providing the body’s first line of defense. Interferon production is inhibited by the virus responsible for COVID-19, the company explained, but AP-003 is designed to bypass the COVID-19-induced interferon production blockade.

BetterLife believes that AP-003 could lessen the severity and duration of COVID-19 and decrease the need for hospital admissions.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: BetterLife Pharma Inc

Price: 0.42096 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $15.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 16/10/20

2 min read